NO20002001L - Peptider i stand til Õ inhibere interaksjonen mellom preseniliner og <beta>-amyloidpeptidet eller dettes forløper - Google Patents

Peptider i stand til Õ inhibere interaksjonen mellom preseniliner og <beta>-amyloidpeptidet eller dettes forløper

Info

Publication number
NO20002001L
NO20002001L NO20002001A NO20002001A NO20002001L NO 20002001 L NO20002001 L NO 20002001L NO 20002001 A NO20002001 A NO 20002001A NO 20002001 A NO20002001 A NO 20002001A NO 20002001 L NO20002001 L NO 20002001L
Authority
NO
Norway
Prior art keywords
interaction
inhibiting
amyloid peptide
precursor
presenilines
Prior art date
Application number
NO20002001A
Other languages
English (en)
Other versions
NO20002001D0 (no
NO328908B1 (no
Inventor
Christian Czech
Luc Mercken
Laurent Pradier
Soline Reboul-Becquart
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9713384A external-priority patent/FR2770217B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20002001D0 publication Critical patent/NO20002001D0/no
Publication of NO20002001L publication Critical patent/NO20002001L/no
Publication of NO328908B1 publication Critical patent/NO328908B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Nye polypeptider i stand til i det minste delvis å inhibere interaksjonen mellom presenilin 1 eller presenilin 2 på den ene side og forløperen av P-amyloidpeptid og/eller P-amyloidpeptid på den annen side.Videre beskrives in vitro-tester for påvisning av molekyler og særlig små molekyler i stand til å inhibere interaksjonen.Oppfinnelsens anvendelse på det farmasøytiske området beskrives.
NO20002001A 1997-10-24 2000-04-17 In vitro anvendelse av et polypeptid som er i stand til a inhibere interaksjonen mellom preseniliner og APP. NO328908B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9713384A FR2770217B1 (fr) 1997-10-24 1997-10-24 Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
US9567198P 1998-08-07 1998-08-07
PCT/FR1998/002278 WO1999021886A1 (fr) 1997-10-24 1998-10-23 PEPTIDES CAPABLES D'INHIBER L'INTERACTION ENTRE LES PRESENILINES ET LE PEPTIDE β-AMYLOIDE OU SON PRECURSEUR

Publications (3)

Publication Number Publication Date
NO20002001D0 NO20002001D0 (no) 2000-04-17
NO20002001L true NO20002001L (no) 2000-04-17
NO328908B1 NO328908B1 (no) 2010-06-14

Family

ID=26233891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002001A NO328908B1 (no) 1997-10-24 2000-04-17 In vitro anvendelse av et polypeptid som er i stand til a inhibere interaksjonen mellom preseniliner og APP.

Country Status (13)

Country Link
EP (1) EP1025121B1 (no)
JP (1) JP2001521043A (no)
KR (1) KR100626475B1 (no)
CN (1) CN100429230C (no)
AU (1) AU766522B2 (no)
BR (1) BR9813105A (no)
CA (1) CA2305816C (no)
CY (1) CY1112236T1 (no)
CZ (1) CZ303226B6 (no)
HU (1) HU227660B1 (no)
IL (2) IL135751A0 (no)
NO (1) NO328908B1 (no)
WO (1) WO1999021886A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303226B6 (cs) * 1997-10-24 2012-06-06 Aventis Pharma S. A. Zpusob detekce nebo izolace sloucenin použitelných pri lécení Alzheimerovy nemoci
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2002074804A2 (en) * 2001-03-16 2002-09-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of binding domains of presenilins and transmembrane proteins for drug screening
CA2641555A1 (en) * 2006-02-06 2007-08-16 Elan Pharmaceuticals, Inc. Preferential inhibition of presenilin-1
JP2009532674A (ja) * 2006-03-31 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 神経変性障害及びアルツハイマー病を治療するための、並びに正常な記憶を改善するための方法と組成物
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
ES2530141B1 (es) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
CN108860921B (zh) 2018-08-08 2020-11-20 上海鸿研物流技术有限公司 可折叠容器

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013069A1 (en) * 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
CZ303226B6 (cs) * 1997-10-24 2012-06-06 Aventis Pharma S. A. Zpusob detekce nebo izolace sloucenin použitelných pri lécení Alzheimerovy nemoci

Also Published As

Publication number Publication date
WO1999021886A1 (fr) 1999-05-06
NO20002001D0 (no) 2000-04-17
AU766522B2 (en) 2003-10-16
CN100429230C (zh) 2008-10-29
CZ303226B6 (cs) 2012-06-06
CZ20001462A3 (cs) 2000-10-11
KR100626475B1 (ko) 2006-09-20
HUP0004605A3 (en) 2002-09-30
CN1277616A (zh) 2000-12-20
CA2305816C (fr) 2012-07-10
CA2305816A1 (fr) 1999-05-06
JP2001521043A (ja) 2001-11-06
IL135751A0 (en) 2001-05-20
AU3129500A (en) 2000-12-14
HUP0004605A1 (hu) 2001-04-28
EP1025121A1 (fr) 2000-08-09
CY1112236T1 (el) 2015-12-09
KR20010024541A (ko) 2001-03-26
HU227660B1 (en) 2011-10-28
NO328908B1 (no) 2010-06-14
BR9813105A (pt) 2000-08-15
IL135751A (en) 2010-12-30
EP1025121B1 (fr) 2011-08-24

Similar Documents

Publication Publication Date Title
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
CA2120358A1 (en) Hormone analogs with multiple ctp extensions
AR019818A1 (es) Un inmunoconjugado de miostatina.
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
DK0883687T3 (da) C-C CKR-5, CC-chemokinreceptor, derivater deraf og anvendelse deraf
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
DE69427370D1 (de) Neue integrinbindende peptide
EP1958961A3 (en) Transport Vectors
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
ES2176284T3 (es) Amidas de peptidos inhibidoras del cancer de seres humanos.
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69938782D1 (de) Peptide als antiangiogene arzneimittel
NO972620D0 (no) RANTES peptid og fragmenter og blandinger omfattende det for behandling av inflammasjon
NO20002001L (no) Peptider i stand til Õ inhibere interaksjonen mellom preseniliner og &lt;beta&gt;-amyloidpeptidet eller dettes forløper
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
NO972849L (no) Peptid p277 analoger og farmasöytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
BR9306272A (pt) Peptídeo e composiçao farmacêutica
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof
ATE276272T1 (de) Entzündungshemmende peptide
IT1277338B1 (it) Composizioni farmaceutiche di ciclosporina o altre sostanze peptidiche
ATE46173T1 (de) Pharmakologisch aktive peptide.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees